Evidence map›Paper›PMID 39184127›Full record

ArticleWellcome open research2024

A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial).

Kathryn Maitland, Nchafasto Obonyo, Mainga Hamaluba, Emmanuel Ogoda, Christabel Mogaka, Thomas N Williams, Charles Newton, Symon M Kariuki, Diana M Gibb, A Sarah Walker and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Wellcome open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kathryn MaitlandDepartment of Infectious Disease and Institute of Global Health and Innovation, Division of Medicine, Imperial College London, London, England, W2 1PG, UK.ORCID https://orcid.org/0000-0002-1862-8109
Nchafasto ObonyoKEMRI Wellcome Trust Research Programme, Kilifi, Kilifi, PO BOX 230, Kenya.ORCID https://orcid.org/0000-0002-5040-4359
Mainga HamalubaKEMRI Wellcome Trust Research Programme, Kilifi, Kilifi, PO BOX 230, Kenya.ORCID https://orcid.org/0000-0002-0266-1414
Emmanuel OgodaKEMRI Wellcome Trust Research Programme, Kilifi, Kilifi, PO BOX 230, Kenya.
Christabel MogakaKEMRI Wellcome Trust Research Programme, Kilifi, Kilifi, PO BOX 230, Kenya.
Thomas N WilliamsDepartment of Infectious Disease and Institute of Global Health and Innovation, Division of Medicine, Imperial College London, London, England, W2 1PG, UK.
Charles NewtonKEMRI Wellcome Trust Research Programme, Kilifi, Kilifi, PO BOX 230, Kenya.ORCID https://orcid.org/0000-0002-6999-5507
Symon M KariukiKEMRI Wellcome Trust Research Programme, Kilifi, Kilifi, PO BOX 230, Kenya.ORCID https://orcid.org/0000-0002-3934-5132
Diana M GibbInstitute of Clinical Trials & Methodology, Medical Research Council Clinical Trials Unit at University College London, London, England, WC1V 6J, UK.ORCID https://orcid.org/0000-0002-9738-5490
A Sarah WalkerInstitute of Clinical Trials & Methodology, Medical Research Council Clinical Trials Unit at University College London, London, England, WC1V 6J, UK.
Roisin ConnonInstitute of Clinical Trials & Methodology, Medical Research Council Clinical Trials Unit at University College London, London, England, WC1V 6J, UK.ORCID https://orcid.org/0000-0002-4408-4336
Elizabeth C GeorgeInstitute of Clinical Trials & Methodology, Medical Research Council Clinical Trials Unit at University College London, London, England, WC1V 6J, UK.

Funding

Wellcome Trust 202800/Z/16/Z
6 · The paper itself

Abstract

Background: African children with cerebral malaria and seizures caused Methods: A Phase I trial conducted in Kilifi, Kenya designed to provide data on safety, feasibility and preliminary data on seizure control using prophylactic ASM (levetiracetam) and BCV as non-invasive ventilatory support in children with cerebral malaria. Children aged 3 months to 12-years hospitalised with Conclusions: This is a Phase I trial largely designed to test the feasibility, tolerability and safety of using non-invasive ventilatory support and LVT prophylaxis in cerebral malaria. Registration: ISRCTN76942974 (5.02.2019); PACTR202112749708968 (20.12.2021).

Indexed as

Africabiphasic cuirass ventilationnchildrenclinical triallevetiracetamnon invasive ventilationprophylactic anticonvulsantssevere malaria

Identifiers

PMID39184127
PMCPMC11342035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.